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Abstract 
AIM: Our main objectives were to evaluate the influence of two-year proton pump inhibitors (PPI) therapy in 
patients with Barrett's oesophagus on its length, in both types, short and long segment. 
METHODS: In this single-centre, prospective interventional controlled study were analysed data collected 
prospectively over two years from patients with Barrett's oesophagus diagnosed by endoscopy. Patients who 
received continuous proton pump inhibitors (PPI) for 2 years were included. At each patient visit symptoms were 
recorded, and at each endoscopy, the length of Barrett's oesophagus (BE) was measured. Biopsies were taken 
along the length of the oesophagus at intervals of 1 cm. In total, 50 patients with Barrett's oesophagus were 
included in the study: 10 of whom had long-segment Barrett's oesophagus, and 40 patients had short-segment 
Barrett's oesophagus. The mean number of endoscopies performed was 3 per patient. 
RESULTS: The length of Barrett's esophagus (BE) was influenced by PPI therapy: Circumferential extension in 
BE patients short-segment Barrett's esophagus (SSBE) (before treatment was 1.5 cm and after treatment was 0.8 
cm Maximum proximal extension in SSBE group before treatment was 2.3 cm (SD ± 1.1 cm), and 1.1 cm (SD ± 
0.9 cm), respectively. Squamous islands were detected in 25% of patients examined after 2 years on PPIs. 
CONCLUSIONS: PPIs achieve a reduction to the length of Barrett's oesophagus, in both types, and the 
development of squamous islands is commonly associated with their use. 
 
 
 
 
 
 
Introduction 
 
In the USA, Barrett's oesophagus (BE) is 
defined as the displacement of the squamocolumnar 
junction proximal to the gastro-oesophagal junction 
with histological evidence of specialised intestinal 
metaplasia on biopsy specimens [1]. The British 
Society of Gastroenterology (BSG) has a different 
definition of Barrett's oesophagus. The BSG defines 
Barrett’s oesophagus as "an endoscopically apparent 
area above the esophagogastric junction that is 
suggestive of Barrett’s oesophagus (salmon-coloured 
mucosa) which is supported by the finding of the 
columnar lined oesophagus on histology". According 
to this definition, areas of intestinal metaplasia, 
although often present, are not a requirement for the 
diagnosis of Barrett's oesophagus [2]. This different 
definition has arisen for several reasons: results from 
multiple studies have demonstrated that specialized 
intestinal metaplasia may be difficult to detect unless 
thorough biopsies are taken; there seem to be cases 
of cancers arising in patients who have 
noninternalized epithelium; and molecular 
abnormalities are present even in nondysplastic 
Barrett’s mucosa [3] [4] [5]. 
The need to standardise the classification of 
Barrett’s oesophagus leads to the development of a 
system known as the Prague classification of Barrett’s 
oesophagus. The Prague C (circumferential) and M 
(maximal extent) criteria were developed and 
validated by Sharma et al., [6] In this classification, 
both the maximal length (M) (including tongues) of 
Barrett's esophagus, as well as the length of the 
circumferential Barrett's segment (C) are measured 
during endoscopy. These numbers can then be used 
to track the length of the Barrett segment over time. 
This system has a high degree of overall validity for 
the endoscopic assessment of the visualised Barrett 
oesophagus segment when it is > 1 cm in length. If 
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the segment is < 1 cm in length, this classification 
system is less valid in its ability to define the length of 
the Barrett segment [6]. Gastroenterologists, at least 
in the USA, agree that endoscopic evidence (salmon-
coloured mucosa proximal to the gastro-oesophageal 
junction) and histologic evidence of specialised 
intestinal metaplasia (that is, the presence of goblet 
cells) are required to make the diagnosis of Barrett's 
oesophagus [1]. 
The goals of gastroesophageal reflux disease 
treatment in patients with Barrett's oesophagus 
include control of symptoms, healing and 
maintenance of healed esophagitis and prevention of 
progression of Barrett's oesophagus toward cancer. 
The first two are fairly easy achievable using either 
medical therapy with proton pump inhibitors (PPI) or 
with antireflux surgery. We have much less data on 
prevention of progression of this disorder, but it would 
certainly appear that if treatment resulted in 
regression of the length of Barrett's oesophagus, it 
might also decrease the risk for progression [7]. 
This study aimed to show whether proton 
pump inhibitors have an impact in the reduction of 
length of Barrett’s oesophagus, in both endoscopic 
types, short segment and long segment Barrett’s 
oesophagus. 
 
 
Material and Methods 
 
This study was performed in University 
Clinical Center of Kosovo, Clinic of 
Gastroenterohepatology and Institute of Pathology in 
Prishtina and Skopje. The time of the investigation 
was June 2009-December 2011. 
In this prospective study, 50 patients with BE 
were included. All patients were interviewed for their 
age, sex, reflux symptoms chronicity, medications 
used, weight, smoking and endoscopic determination 
of hiatal hernia presence. All endoscopic procedures 
were performed by 1 of 2 experienced endoscopists 
(having performed > 10.000 gastroscopies each). 
Upper endoscopy was performed by using the 
Videogastroscope GIF type Q 145 series.  
Endoscopic respondents were investigated by 
the following dynamics: 
In the first endoscopy, endoscopic BE 
diagnosis was obtained in the terrain of Gastro-
esophageal Reflux Disease (GERD) changes, the 
presence of a hiatus hernia was diagnosed, as well as 
macroscopic classification of Barrett's esophagus as 
short (SSBE < 3 cm) and long (LSBE > 3 cm) 
segment of Barrett’s esophagus. Patients for two 
years were treated with PPI with maximal doses 
(lansoprazole 2 x 30 mg or pantoprazole 2 x 40 mg, 
30 min before meals). 
Two months following the first endoscopy, 
repeat endoscopy with multiple biopsies from the BE 
zone, 10-15 biopsies, according to “settle-protocol”. 
Patients were continued to be treated with PPI for two 
years. If necessary, in subjects with more pronounced 
complaints of vomiting and reflux, antiemetic drugs 
were administered for up to two weeks.  
After 2 years of follow-up, period endoscopy 
was performed on the respondents to determine 
eventual changes in Barrett’s length and to perform (C 
& M) multiple biopsies for microscopic analysis. 
Endoscopic assessment is carried out by the so-called 
Prague C and M criteria, representing endoscopic 
grading of changes in Barrett's oesophagus. This 
system includes circumferential (C) and the maximum 
proximal extension (M) of the columnar epithelium 
over the gastro-oesophagal junction, which in this 
case is as defined top (proximal) border of the gastric 
folds present. The distance to determine changes in 
length measured from the anterior dental arch 
expressed in centimetres (cm). Short (SSBE) and long 
(LSBE) segment of Barrett's oesophagus was 
determined by the length of the segment containing 
specialised intestinal epithelium (< 3 cm and > 3 cm, 
respectively). At each endoscopy, the location of the 
GEJ is defined as a place that the highest gastric fold 
in the tubular oesophagus meets. The length of 
Barrett's oesophagus was measured from the site of 
the highest point of squamo - cylindric transition. A 
hiatal hernia was diagnosed when the crural 
impression was separated from the top of the gastric 
rugal folds by 2 or more centimetres. The size of a 
hiatal hernia was recorded in centimetres.  
Gastro-oesophageal junction (GEJ) is an 
imaginary line where the oesophagus ends, and the 
stomach begins. The highest point line with gastric 
folds was proposed as a marker for GEJ. The 
difference between the endoscopically located 
squamocolumnar junction and the endoscopically 
estimated gastro-oesophagal junction determined the 
length of Barrett’s oesophagus. The positions of 
endoscopic markings were determined in centimetres 
from the incisors in documenting the level of 
esophagitis and squamocolumnar connection, along 
with the cylindrical extension of the lower oesophagus 
and the upper limit of gastric folds. 
Histological processing was performed in the 
Institute of Pathology in Prishtina and Skopje. 
Biopsies were taken from the mucosa changes at 
intervals of 2cm, and the samples separately from 
each level were processed in formalin and paraffin. 
Afterwards, a series of sections were cut and marked 
with haematoxylin-eosin, alcian- blue and Giemsa- 
colour. The same experienced expert pathologist 
reviewed all biopsy specimens. The pathologist was 
not aware of the treatment applied. The recognition of 
intestinal metaplasia by biopsy, especially goblet cells, 
can be facilitated with the use of alcian blue stain of 
pH 2.5. 
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Calculation of sample size was made based 
on the data for patients with BE in the GERD group 
patients, which was 10% in most of the studies. 
However, for higher security, the sample size was 
calculated as 15%. 
The results were analysed with modern 
statistical methods. Data processing was performed 
with Instant 3 statistical package. Statistical 
parameters were calculated from the index structure, 
mean, standard deviation, minimum and maximum 
value. The test data used parametric t-test (for 
variables with normal distribution, values were shown 
as a mean and standard deviation, and the 
differences between them were tested by the 
arithmetic mean of the differences). The difference 
was considered significant if P < 0.05. 
 
 
Results 
 
The study included 50 patients with BE. The 
average age of patients in Group BE was 52.4 years 
(SD ± 10.8 yrs). In the group of patients with BE, most 
common age group was 50-59 years. In the group 
with BE, 78.0% were men. 
Average body height of respondents in BE 
group was 174.8 cm (SD ± 8.2 cm), although 60% of 
BE patients were smokers. Patients in BE group 
smoked more cigarettes, in 60% of patients. Patients 
in BE group had higher Body mass index (29.5). 
The duration of symptoms in BE group was 
7.8 years. (SD ± 2.16 yrs). In the BE group, 40 (80%) 
patients had hiatal hernia, of which 29 or 74.4.0% 
were < 3 cm (SSBE), and 11 or 100% were > 3 cm 
(LSBE). 
Our results for the presence of a hiatal hernia 
by endoscopic type of BE are presented in the 
following table. Although without significant difference, 
the presence of a hiatal hernia was greater in the 
subgroup with LSBE. 
Table 1: The presence of a hiatal hernia by endoscopic type of 
BE 
 
A hiatal hernia 
Total 
Yes No 
SSBE 
N 29 10 39 
% 74.4 25.6 100.0 
LSBE 
N 11 - 11 
% 100.0 - 100.0 
Total 
N 40 10 50 
% 80.0 20.0 100.0 
Z-value Z = 1.87, P = 0.607  
 
Circumferential extension in BE patients with 
SSBE before treatment was 1.5 cm (SD ± 0.7 cm), 
and after treatment was 0.8 cm (SD ± 0.1 cm). The T-
test of mediocrity received the significant difference in 
circumferential spreading the SSBE group before vs 
after treatment (T = 7.0, P < 0.0001) (Table 2, Fig. 1 
and Fig. 2). 
Table 2: The effect of PPI treatment by Prague C & M 
classification in patients with BE 
BE 
Circumferential extent 
Median value ± SD 
Maximal proximal extent 
Median value ± SD 
Before After Before After 
SSBE 
n=39 1.5 ± 0.7 0.8 ± 0.1 2.3 ± 1.1 1.1 ± 0.9 
T-test paired sample T = 7.0, P < 0.0001 T = 5.97, P < 0.0001 
LSBE 
n=11 2.5 ± 1.1 1.4 ± 0.8 4.3 ± 1.9 2.3 ± 1.7 
T-test paired sample T = 5.71, P < 0.0001 T = 5.54, P < 0.0001 
 
Maximum proximal extension with this group 
before treatment was 2.3 cm (SD ± 1.1 cm), and after 
treatment 1.1 cm (SD ± 0.9 cm). The T-test of 
mediocrity received the significant difference in 
maximum proximal extension in the group before 
SSBE vs after treatment (t = 5.97, P < 0.0001). 
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Figure 1: Maximal circumference of BE prior and after treatment 
with PPI based on Prague C & M 
 
Circumferential extension in BE patients with 
LSBE before treatment was 2.5 cm (SD ± 1.1 cm), 
and after treatment was 1.4 cm (SD ± 0.8 cm). The T-
test of mediocrity received the significant difference in 
the stretching group circumferential LSBE before vs 
after treatment (T = 5.71, P < 0.0001). Maximum 
proximal extension with this group before treatment 
was 4.3 cm (SD ± 1.9 cm), and after treatment 2.3 cm 
(SD ± 1.7 cm). The T-test of mediocrity received the 
significant difference in maximum proximal extension 
with LSBE group before vs after treatment (t = 5.54, P 
< 0.0001). 
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Figure 2: Maximal length of BE prior and after treatment with PPI 
based on Prague C & M 
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Discussion 
 
Therapy with PPI showed that long-term 
safety reduces exposure to acid and prevents the 
development of dysplasia [8]. The results of our study 
may be useful to encourage all patients with Barrett's 
oesophagus to continue therapy with PPI, for long-
term, to prevent dysplasia, even if they had symptoms 
or esophagitis. Furthermore, cases of Barrett's 
oesophagus can be divided according to the length of 
the segment of Barrett's oesophagus. BE patients with 
a short segment is defined as intestinal metaplasia of 
the distal oesophagus when the length is less than 3 
cm. Disease with long segment refers to cases when 
intestinal metaplasia of the distal oesophagus is 
measured 3cm or more. Our results show that the BE 
circumferential changes in patients with SSBE before 
treatment was 1.5 cm (SD ± 0.7 cm), and after 
treatment has fallen to 0.8cm (SD ± 0.1 cm) (P < 
0.0001), circumferential BE extension in patients with 
LSBE before treatment was 2.5 cm (SD ± 1.1 cm), 
and after treatment was 1.4 cm (SD ± 0.8 cm) (P < 
0.0001). Maximum proximal extension in this group 
before treatment was 4.3 cm (SD ± 1.9 cm), and after 
treatment 2.3 cm (SD ± 1.7 cm) (P < 0.0001). 
There are few studies in the literature on this 
topic. Sampliner [9] studied 27 patients treated for 
almost 3 years with lansoprazole 60 mg daily. There 
was no reduction in the segment of Barrett-
esophagus, but 62% of patients developed islands in 
plate epithelium. In one study Sharma et al., [10] 
followed up 13 patients, for an average period of 5.7 
years, who received lansoprazole 30 mg twice daily. 
There was no reduction of Barrett's oesophagus or 
complete control of acidity in the oesophagus 
(documented by pH testing). Extensive study with 47 
patients treated with different doses of omeprazole 
also showed the appearance of islets of plate 
epithelium, but not completely cut the length of the 
Barrett-'s segment of the oesophagus. A 12 months 
study conducted by Malesci et al., [11] showed a total 
reduction of 4.5 to 2.1 cm with a 12-month 
suppression of acidity. These data show the most 
impressive reduction in the length of Barrett's 
oesophagus to date and they are difficult to replicate. 
Recently, Srinivasan et al., [12] reported 
about 9 patients who had complete control of 
oesophagal acidity using PPI twice daily, with a 
histamine blocker, at night. This treatment resulted in 
a slight decrease in the average length of Barrett's 
oesophagus, from 7.2 to 5.2 cm reaching statistical 
value (P < 0.001). Indeed, histamine blockers could 
not produce any islands of epithelium plate or reduced 
length of Barrett's oesophagus in these studies. In an 
extensive review of the literature concerning this topic, 
only 3 patients described complete withdrawal of 
Barrett's oesophagus following treatment with PPI. 
Interestingly, the short-segment disease is at 
least 3 times more prevalent than long-segment 
disease [13] [14] [15],
 
and the length of the long 
segment is associated with greater exposure to acid 
[16]. But once Barrett's oesophagus is present its 
overall length does not change, so the disease with a 
short segment normally remains short [17]. The 
degree of dysplasia is directly related to the length of 
the segment [18] [19]. However, variants with a long 
or short segment of Barrett's oesophagus associated 
with the development of dysplasia and 
adenocarcinoma regarding monitoring and 
endoscopic treatment are both treated similarly [20]. 
In conclusion, the age group of 50-59 years, 
male gender, smokers and alcohol consumer are 
important predictive factors for the development of BE 
among patients with GERD. Obesity, age, male 
gender, smoking is also an important factor in the 
development of the BE, so far as it is represented. A 
hiatal hernia is confirmed to be an important factor in 
the occurrence of Barrett’s oesophagus since it was 
present in a high rate in both endoscopic types (74% 
in SSBE and 100% in LSBE). We confirmed that PPI 
therapy is useful for long-term safety and the 
regression of macroscopic changes of BE due to 
reduced exposure of the distal oesophagus to gastric 
acid.  
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